These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 27277678)
1. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678 [TBL] [Abstract][Full Text] [Related]
2. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
3. Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity. Langdon CG; Gadek KE; Garcia MR; Evans MK; Reed KB; Bush M; Hanna JA; Drummond CJ; Maguire MC; Leavey PJ; Finkelstein D; Jin H; Schreiner PA; Rehg JE; Hatley ME Nat Commun; 2021 Sep; 12(1):5520. PubMed ID: 34535684 [TBL] [Abstract][Full Text] [Related]
4. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
5. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
6. Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor-Significance of Tumor Subclones. Skrzypek K; Adamek G; Kot M; Badyra B; Majka M Cells; 2021 Jul; 10(8):. PubMed ID: 34440639 [TBL] [Abstract][Full Text] [Related]
7. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors. de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386 [TBL] [Abstract][Full Text] [Related]
8. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971 [TBL] [Abstract][Full Text] [Related]
9. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Li L; Sarver AL; Alamgir S; Subramanian S Lab Invest; 2012 Apr; 92(4):571-83. PubMed ID: 22330340 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells. Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328 [TBL] [Abstract][Full Text] [Related]
12. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430 [TBL] [Abstract][Full Text] [Related]
13. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375 [TBL] [Abstract][Full Text] [Related]
14. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116 [TBL] [Abstract][Full Text] [Related]
16. The role of microRNA-1 and microRNA-206 in the proliferation and differentiation of bovine skeletal muscle satellite cells. Dai Y; Wang YM; Zhang WR; Liu XF; Li X; Ding XB; Guo H In Vitro Cell Dev Biol Anim; 2016 Jan; 52(1):27-34. PubMed ID: 26424132 [TBL] [Abstract][Full Text] [Related]
17. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells. De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362 [TBL] [Abstract][Full Text] [Related]
18. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344 [TBL] [Abstract][Full Text] [Related]
19. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Tiffin N; Williams RD; Shipley J; Pritchard-Jones K Br J Cancer; 2003 Jul; 89(2):327-32. PubMed ID: 12865925 [TBL] [Abstract][Full Text] [Related]
20. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]